Zynex (ZYXI) Competitors $1.52 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.53 +0.01 (+0.66%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYXI vs. INFU, INGN, PROF, ELMD, PDEX, LNSR, TLSI, LAKE, AVR, and BSGMShould you be buying Zynex stock or one of its competitors? The main competitors of Zynex include InfuSystem (INFU), Inogen (INGN), Profound Medical (PROF), Electromed (ELMD), Pro-Dex (PDEX), LENSAR (LNSR), TriSalus Life Sciences (TLSI), Lakeland Industries (LAKE), Anteris Technologies Global (AVR), and Biosig Technologies (BSGM). These companies are all part of the "medical equipment" industry. Zynex vs. Its Competitors InfuSystem Inogen Profound Medical Electromed Pro-Dex LENSAR TriSalus Life Sciences Lakeland Industries Anteris Technologies Global Biosig Technologies Zynex (NASDAQ:ZYXI) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Which has better valuation and earnings, ZYXI or INFU? Zynex has higher revenue and earnings than InfuSystem. Zynex is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZynex$192.35M0.24$2.99M-$0.94-1.62InfuSystem$139.89M1.39$870K$0.2341.43 Do institutionals & insiders believe in ZYXI or INFU? 29.7% of Zynex shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 49.3% of Zynex shares are held by insiders. Comparatively, 11.4% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor ZYXI or INFU? In the previous week, Zynex had 5 more articles in the media than InfuSystem. MarketBeat recorded 5 mentions for Zynex and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.60 beat Zynex's score of 0.57 indicating that InfuSystem is being referred to more favorably in the news media. Company Overall Sentiment Zynex Positive InfuSystem Positive Is ZYXI or INFU more profitable? InfuSystem has a net margin of 1.12% compared to Zynex's net margin of -19.79%. InfuSystem's return on equity of 2.78% beat Zynex's return on equity.Company Net Margins Return on Equity Return on Assets Zynex-19.79% -78.54% -16.70% InfuSystem 1.12%2.78%1.41% Do analysts rate ZYXI or INFU? Zynex presently has a consensus target price of $4.90, indicating a potential upside of 222.37%. InfuSystem has a consensus target price of $12.50, indicating a potential upside of 31.16%. Given Zynex's higher probable upside, equities analysts plainly believe Zynex is more favorable than InfuSystem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zynex 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33InfuSystem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 3 Strong Buy rating(s) 4.00 Which has more risk and volatility, ZYXI or INFU? Zynex has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. SummaryInfuSystem beats Zynex on 11 of the 17 factors compared between the two stocks. Get Zynex News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYXI vs. The Competition Export to ExcelMetricZynexMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.06M$10.48B$5.70B$9.79BDividend YieldN/A1.90%3.77%4.10%P/E Ratio-1.6220.6330.8625.25Price / Sales0.2433.19403.9088.50Price / Cash6.2224.9525.2228.45Price / Book1.363.459.516.00Net Income$2.99M$209.94M$3.26B$265.34M7 Day Performance7.04%3.88%4.49%2.81%1 Month Performance-34.20%12.50%5.18%1.50%1 Year Performance-80.41%-9.26%31.98%25.46% Zynex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYXIZynex2.6426 of 5 stars$1.52flat$4.90+222.4%-80.4%$46.06M$192.35M-1.62770INFUInfuSystem3.4342 of 5 stars$8.60-2.6%$12.50+45.3%N/A$175.66M$139.89M143.36410High Trading VolumeINGNInogen4.3829 of 5 stars$7.04+8.6%$11.00+56.3%-41.9%$174.23M$335.70M-6.641,030PROFProfound Medical1.7447 of 5 stars$5.63+1.6%$11.00+95.4%-53.0%$166.49M$10.68M-4.61150Earnings ReportGap UpELMDElectromed1.212 of 5 stars$19.15+2.7%$33.50+74.9%+25.0%$160.59M$61.44M25.53160PDEXPro-Dex3.0983 of 5 stars$38.41-19.6%$56.00+45.8%+116.4%$155.71M$53.84M13.72140News CoverageAnalyst DowngradeHigh Trading VolumeLNSRLENSAR1.0454 of 5 stars$13.03+1.2%$15.00+15.1%+189.5%$151.76M$53.49M-3.10110Positive NewsTLSITriSalus Life Sciences3.1919 of 5 stars$3.57-9.6%$10.75+201.1%-20.9%$149.46M$29.43M-3.19106News CoverageEarnings ReportAnalyst RevisionLAKELakeland Industries4.7766 of 5 stars$13.76-2.6%$26.00+89.0%-37.8%$134.44M$167.21M-4.572,100Earnings ReportAVRAnteris Technologies GlobalN/A$3.50-3.3%$16.50+371.4%N/A$130.54M$2.70M0.00138Earnings ReportGap UpBSGMBiosig Technologies1.9681 of 5 stars$4.09+9.1%$10.00+144.5%+935.4%$117.47M$40K0.0050Earnings ReportGap Down Related Companies and Tools Related Companies InfuSystem Alternatives Inogen Alternatives Profound Medical Alternatives Electromed Alternatives Pro-Dex Alternatives LENSAR Alternatives TriSalus Life Sciences Alternatives Lakeland Industries Alternatives Anteris Technologies Global Alternatives Biosig Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYXI) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zynex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access